Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
17088998
Knihovny.cz E-resources
- MeSH
- Genes, MHC Class I genetics immunology MeSH
- Immunotherapy methods MeSH
- Papillomavirus Infections complications immunology virology MeSH
- Combined Modality Therapy MeSH
- Human papillomavirus 16 isolation & purification MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Lung Neoplasms immunology pathology therapy virology MeSH
- Interleukin-2 Receptor alpha Subunit immunology MeSH
- T-Lymphocytes, Regulatory immunology MeSH
- Neoplasm, Residual MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Interleukin-2 Receptor alpha Subunit MeSH
It is generally accepted that T regulatory cells (T(reg) CD4(+)CD25(+)Foxp3(+)) play an important role in the suppression of tumour immunity. We examined the impact of T(reg) cell depletion with anti-CD25 antibody as adjuvant therapy in the treatment of minimal residual disease after excision of murine HPV16-associated tumours. We found that the depletion of T(reg) cells inhibited growth of the recurrences after surgery of HPV16-associated MHC class I+ as well as MHC class I-deficient tumours transplanted in syngeneic mice. These results demonstrate that depletion of CD25(+)CD4(+) T(reg) cells can be used as an efficient adjuvant treatment improving the results of surgery in the experimental systems mimicking human MHC class I+ and MHC class I-deficient, HPV16-associated neoplasms. Therefore, this therapeutic modality is worth being examined in patients with minimal residual HPV16-associated tumour disease after surgery.
